Investigational Agents Targeting SGLT1 and SGLT2 in the Treatment of Type 2 Diabetes Mellitus.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Bentham Science Publishers Country of Publication: United Arab Emirates NLM ID: 100960531 Publication Model: Print Cited Medium: Internet ISSN: 1873-5592 (Electronic) Linking ISSN: 13894501 NLM ISO Abbreviation: Curr Drug Targets Subsets: MEDLINE
    • Publication Information:
      Publication: Saif Zone, Sharjah, U. A. E. : Bentham Science Publishers
      Original Publication: Hilversum, Netherlands ; Boca Raton, FL : Bentham Science Publishers, c2000-
    • Subject Terms:
      Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/chemically induced ; Sodium-Glucose Transporter 2 Inhibitors*/pharmacology ; Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use; Humans ; Hypoglycemic Agents/adverse effects ; Sodium-Glucose Transporter 2/therapeutic use ; Kidney
    • Abstract:
      Targeting sodium-dependent glucose transporters (SGLT1 and SGLT2) represents a new class of pharmacotherapy for type 2 diabetes mellitus, a major global health issue with an increasing social and economic burden. Following recent successes in market approvals of SGLT2 inhibitors, the ongoing effort has paved the way for the discovery of novel agents via structure-activity relationship studies, preclinical and clinical testing, including SGLT2 inhibitors, SGLT1/2 dual inhibitors, and selective SGLT1 inhibitors. A growing understanding of the physiology of SGLTs allows drug developers to explore additional cardiovascular and renal protective benefits of these agents in T2DM patients at risk. This review provides an overview of the recent investigational compounds and discusses future perspectives of drug discovery in this area.
      (Copyright© Bentham Science Publishers; For any queries, please email at [email protected].)
    • Contributed Indexing:
      Keywords: HbA1c; SGLT1; SGLT2; fasting plasma glucose; glycemic control; type 2 diabetes mellitus; urine glucose excretion
    • Accession Number:
      0 (Sodium-Glucose Transporter 2 Inhibitors)
      0 (Hypoglycemic Agents)
      0 (Sodium-Glucose Transporter 2)
    • Publication Date:
      Date Created: 20230504 Date Completed: 20230829 Latest Revision: 20230902
    • Publication Date:
      20240628
    • Accession Number:
      10.2174/1389450124666230503120930
    • Accession Number:
      37138489